Ads
related to: 7.5 intramuscular injection sites
Search results
Results From The WOW.Com Content Network
In transgender women, estradiol valerate given by intramuscular injection is usually used at a dosage of 5 to 20 mg, but up to 30 to 40 mg, once every 2 weeks. [30] [31] [29] Estradiol valerate has also been used at a dose of 10 to 40 mg by intramuscular injection to limit bleeding in women with hemorrhage due to dysfunctional uterine bleeding.
Estradiol cypionate is usually used at a dosage of 1 to 5 mg by intramuscular injection every 3 to 4 weeks in the treatment of menopausal symptoms such as hot flashes and vaginal atrophy, at a dosage of 1.5 to 2 mg by intramuscular injection once a month in the treatment of female hypoestrogenism due to hypogonadism, and at a dosage of 2 to 10 ...
The term injection encompasses intravenous (IV), intramuscular (IM), subcutaneous (SC) and intradermal (ID) administration. [35] Parenteral administration generally acts more rapidly than topical or enteral administration, with onset of action often occurring in 15–30 seconds for IV, 10–20 minutes for IM and 15–30 minutes for SC. [36]
Estradiol benzoate is and has been available as an oil solution for intramuscular injection provided as vials and ampoules at concentrations of 0.167, 0.2, 0.33, 1, 1.67, 2, 5, 10, 20, and 25 mg/mL. [23] [31] [8] It is also available as a microcrystalline aqueous suspension for intramuscular injection under the brand name Agofollin Depot.
CICs are administered by intramuscular injection into the deltoid, gluteus maximus, or anterior thigh. [1] They are ideally administered every 28 to 30 days, though they have been demonstrated to be effective up to 33 days. [1] Some CICs have been said to be used by transgender women as a means of feminizing hormone therapy as well. [12]
GnRH antagonists are administered by subcutaneous injection (cetrorelix, degarelix, ganirelix), by intramuscular injection (abarelix), or by oral administration (elagolix, relugolix). Another non-peptide and orally-active GnRH antagonist that is in development is linzagolix. [17]
The trials were conducted at 30 sites in the United States and Canada. [64] Both trials enrolled participants 18 to 75 years old with moderate to severe glabellar lines. [64] Participants received a single intramuscular injection of daxibotulinumtoxinA or placebo at five sites within the muscles between the eyebrows. [64]
Note: All by intramuscular injection. Footnotes: a = Microcrystalline or nanocrystalline aqueous suspension. b = Low-viscosity vegetable oil (specifically fractionated coconut oil with medium-chain triglycerides). c = Predicted, from PubChem and DrugBank. Sources: Main: See template.